Navigation Links
Experimental drug boosts survival in recurrent ovarian cancer
Date:9/27/2007

BIRMINGHAM, Ala. New clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor said recently.

The data was presented Sept. 24 during a scientific session of the 14th European Cancer Conference held in Barcelona, Spain. The sessions main speaker was Sharmila Makhija, M.D., an associate professor in UABs Division of Gynecologic Oncology.

Makhija said Phase II clinical trial data showed that pertuzumab added weeks to the lives of Stage 3 ovarian cancer patients whose disease had returned after treatment with existing chemotherapy regimens.

In the study, pertuzumab was administered in combination with a standard chemotherapy agent sometime after the initial treatments had been given, and after the re-emergence of cancer. Makhija said the new combination added weeks to the standard survival period for recurrent patients, and the drug combo was well-tolerated by the body and caused minimal side effects.

"We wanted to know if pertuzumab would improve the effects of the chemotherapy with cancer recurrence, and if it would improve their lives. It did," Makhija said. "Now we want to see if it impacts overall survival."

Once ovarian cancer becomes resistant to multiple types of chemotherapy, fewer treatment options exist and the focus becomes lengthening patients survival periods.

The pertuzumab trial included 130 women enrolled by UAB, Dana-Farber Cancer Institute and Dana-Farber/Brigham and Women's Cancer Center in Boston, University of Kentucky Chandler Medical Centers Markey Cancer Center in Lexington, Women and Infants Hospital of Rhode Island in Providence, Sharp Rees-Stealy Medical Group in San Diego, University of Oklahoma Health Sciences Center in Oklahoma City. Study costs were paid by Genentech Inc. in South San Francisco, Calif.

Makhija presented the same results earlier this year at the 2007 American Society of Clinical Oncology meeting in Chicago.

Makhija said the Phase II study is now closed, and researchers are in the planning stages for a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women.

Pertuzumab is approved only for experimental uses. It falls within a class of anticancer agents called monoclonal antibodies. Such drugs target key signaling pathways within cells that can stop or slow tumor growth.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers ... under the USDA National Organic Program (NOP) for its Portland SQF Level 2 ... organic production and handling systems to complement our current rigorous food-safety management systems,” ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “The Inn at the Mill”: a story ... fears in her quest to become happy and content. , “The Inn at the ... has also lived in Germany and Vermont and is now living in Berks County on ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
(Date:1/21/2017)... ... 21, 2017 , ... Caronlab Australia, an Australian company known for health and ... Hilton Head, SC, where it benefited from outstanding meetings with major retail buyers. , ... wellness products. At this trade show, the company had the chance to demonstrate its ...
(Date:1/21/2017)... Barbara, CA (PRWEB) , ... January 21, 2017 ... ... its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for ... festivities for alumni, family, friends, and community. “Coming Home 2017” will be ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Based on its ... & Sullivan recognizes Ansell, a global leader in ... Sullivan Company of the Year Award. Ansell,s comprehensive ... a wide global footprint have placed it in ... protection market. The Company,s established product line and ...
(Date:1/23/2017)... , Jan. 23, 2017 Research and ... Market - Forecast to 2021" report to their offering. ... The interventional radiology ... from USD 6.35 Billion in 2016, at a CAGR of 4.8%. ... The major factors driving the growth of this market ...
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
Breaking Medicine Technology: